. 2021 Feb 16;93(5):3077–3083. doi: 10.1002/jmv.26853

Table 2.

Laboratory data of patients with COVID‐19 accoding to clinical course

	Asymptomatic (n = 84)	Mild (n = 309)	Moderate (n = 105)	Severe/ Critical (n = 20)	p value
Delta Ct (median, IQR)	2.4 (‐1.0, 5)	0 (‐2.9, 3.7)	0.9 (‐3.5, 4.8)	1.6 (‐1.6, 4.7)	>0.05^a, ^b, ^c
Increased CRP (n, %)	4/62 (6.5)	34/201 (16.9)	19/93 (20.4)	14/20 (70)	0.001^a
					0.001^b
					0.001^c
Increased LDH (n, %)	11/43 (25.6)	26/164 (15.9)	12/75 (16)	10/18 (55.6)	0.02^a
					0.001^b
					0.001^c
Procalcitonin µg/L (median, IQR)	0.04 (0.03‐0.07)	0.05 (0.04‐0.09)	0.05 (0.04‐0.89)	0.14 (0.07‐2.8)	0.001^a
					0.001^b
					0.001^c
White blood cell x10⁶/µL (median, IQR)	5900 (3200‐7800)	6200 (4500‐8200)	5900 (4600‐7600)	7800 (4600‐10800)	>0.05^a, ^b, ^c
ANC x10⁶/µL (median, IQR)	2400 (1500‐3500)	3000 (2000‐4700)	2700 (2000‐4300)	3500 (1700‐7600)	>0.05^a, ^b, ^c
ALC x10⁶/µL (median, IQR)	2900 (1900‐4100)	2100 (1400‐3000)	2000 (1200‐2900)	1100 (500‐2400)	0.001
					0.04
					>0.05^c
Thrombocyte x10⁹/µL (median, IQR)	283 (232‐334)	245 (210‐296)	259 (220‐312)	199 (159‐232)	0.001^a
					0.01^b
					0.001^c

ALS: Absolute lypmhocyte count. ANS: Absolute neutrophil count. CRP; C‐reactive protein. LDH:Lactate dehydrogenase.

^{^a}

Asymptomatic vs. Severe/Critical.

^{^b}

Mild. vs. Severe/Critical.

^{^c}

Moderate vs. Severe/Critical.